Table 2 : Rituximab in the Treatment of Primary Intraocular Lymphoma.


Author  Route Dose Combination Eyes Treated Response Rate Relapse Rate Median Relapse Median Follow-up

Batchelor et al.,[60] IV 375 mg/m2 - PCNSL 5/12 4/5 19 months 64.3 months
Vosganian et al.,[68] IV 500 mg/m2 HD-MTX, EBRT 1 1/1 1/1 16 months 19 months
Turaka et al.,[69] IVT 1 mg IVT MTX 2 2/2 0/2 - 33.5 moths
Yeh et al.,[14] IVT 1 mg IVT MTX 1 1/1 0/1 - 18 months
Hashida et al.,[70] IVT 1 mg  - 20 20/20 11/20 3 months 31 months

IV, intravenous; IVT, intravitreal; HD-MTX, high dose methotrexate; EBRT, external beam radiation therapy; MTX, methotrexate; PCNSL, primary central nervous system lymphoma.

Alexandru et al.Journal of Cancer Therapeutics and Research  2013 2:15DOI : 10.7243/2049-7962-2-15